ICCC vs KEY · rev $26.5M vs P/E 13, rev $7.51B
ImmuCell Corporation (ICCC) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported ICCC revenue for 2024-12-31 was $26.5M. Net income was -$2.2M. Revenue was up 51.6% from 2023-12-31 to 2024-12-31. ICCC currently screens at market cap $58.9M.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
ICCC currently screens at market cap $58.9M. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the ICCC and KEY stock pages for the full models.
Not investment advice.